Linear Clinical Research Joins CTA Member Network

/Linear Clinical Research Joins CTA Member Network

Linear Clinical Research Joins CTA Member Network

Cancer Trials Australia (CTA) is pleased to announce that Linear Clinical Research has signed a Members Agreement to join the CTA Member Network

The CTA network now includes 24 members, comprising 22 clinical sites and 2 research institutes, across 4 Australian states.  Collaboration across these members provides a great opportunity for both sponsors and investigators to conduct multi-site clinical trials, accruing significant patient numbers quickly, despite Australia’s relatively small population.

Established in Perth in 2010, Linear Clinical Research was formed as a collaborative venture between The Harry Perkins Institute and the Departments of Health and Commerce. Since inception, they have undertaken over 150 early-phase to late-phase clinical trials across 19 therapeutic areas, including oncology. The Linear facilities include a state-of-the-art 32 bed facility, 10 consulting suites, on-site monitoring, pharmacy and quality assurance.

Dr. Michael Winlo, CEO of Linear, heads over 100 staff – comprising 5 consultant oncologists, a full-time oncology fellow, specialist oncology nurses and a global collaborator network.   Linear’s oncology trial volume continues to grow rapidly, with more than 20 recruiting at present. “Our membership with Cancer Trials Australia will provide Linear’s cancer specialists access to a national expert network.  Our involvement confirms CTA as a truly national initiative and supports Linear’s mission to bring new therapies to patients faster” said Dr Winlo.

CTA and Linear have a strong history of working together in undertaking Phase 1 clinical trials. The inclusion of Linear into CTA’s membership provides the CTA member network with an additional, experienced Phase 1 capable site, an important presence in Western Australia, and an increasingly national profile in the oncology clinical trial ecosystem.

“Linear has developed an excellent reputation for first-time-in-human oncology trials which, coupled with their innovation in key areas such as electronic document capture, and strong relationships with both pharma and contract research organisations, will add significant weight to the CTA network.” said Dr Kurt Lackovic, CEO Cancer Trials Australia.

Additional information can be found at the Linear website: http://www.linear.org.au/

By | 2017-08-28T04:16:34+00:00 August 28th, 2017|General|0 Comments